GW Pharma (GWPH) Tops Q3 EPS by 80c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GW Pharma (GWPH) PT Trimmed to $175 at Cowen, Bullish on Epidiolex Uptake
November 3, 2020 1:41 PM ESTCowen analyst Phil Nadeau lowered the price target on GW Pharma (NASDAQ: GWPH) to $175.00 (from $180.00) while maintaining an Outperform rating.
despite the price target cut, the analyst notes Epidiolex uptake was ahead of consensus with much room to... MoreGW Pharma (GWPH) Begins Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
November 3, 2020 7:22 AM ESTGW Pharmaceuticals plc (NASDAQ: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity. Nabiximols, known as Sativex® outside of the U.S. and approved for use to treat MS spasticity in over 25 countries, is a complex botanical medicine formulated from extracts of the cannabis plant administered as an oral spray. Positive results from three previous European Phase 3 clinical studies show nabiximols... More
